CHI3L1 and early-onset autosomal dominant Alzheimer disease: One of the transcripts significantly changed by CT1812 treatment, CHI3L1, which encodes YKL-40 protein, is expressed in astrocytes and is a biomarker of inflammation in Alzheimer’s disease [48].